• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Disease modifying therapies likely to reduce conversion to secondary progressing multiple sclerosis

byDaniel Fisher
January 16, 2019
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this case-control cohort study, treatment with glatiramer acetate, interferon-beta, fingolimod, alemtuzumab, and natalizumab all led to reduced conversion to secondary progressive Multiple Sclerosis (MS) compared to no Disease-Modifying Treatment (DMT).

2. Treatment with fingolimod, alemtuzumab, and natalizumab had reduced conversion to secondary progressive MS compared to glatiramer acetate and interferon-beta.

Evidence Rating Level: 2 (Good)

Study Rundown: Patients with relapsing-remitting MS generally convert to secondary progressive MS within a few decades of initial diagnosis. Though Disease Modifying Therapies (DMTs) are well-validated to treat MS symptoms and prevent exacerbations, it is unclear if they similarly reduce the conversion to secondary progressive MS. In this case-control cohort with prospectively collected clinical data, patients who received any DMT had reduced conversion to secondary progressive MS than those who did not. Further, those who received DMT closer to symptom appearance tended to have reduced conversion compared to those who started DMT later. The more potent DMTs studied (fingolimod, alemtuzumab, and natalizumab) had reduced conversion compared to glatiramer acetate and interferon-beta.

This study utilizes the newly set consensus definition for secondary progressive MS, and thus may be more accurate than similar studies completed previously. However, the study was limited by its cohort design and strict exclusion criteria that greatly reduced the proportion of patients eligible for study.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

RELATED REPORTS

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

Improvements in therapeutic and managing standards associated with significant reduction in risk of persistent disability in patients with pediatric-onset multiple sclerosis

Relevant Reading: Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis

In-Depth [case-control study]: 1555 matched patients with relapsing-remitting MS (out of 44,217 assessed for eligibility) were included in this observational cohort study with prospectively collected clinical data from 3 databases from the UK: untreated patients from a neuroinflammatory service database from the University Hospital of Wales, treated patients from MSBase, and atelezumab-treated patients from 5 European, non-MSBase centers. Patients were included if they had primary relapsing-remitting MS, complete MSBase minimal dataset, at least one Extended Disability Status Scale (EDSS) score 6 months before baseline, and at least 2 EDSS scores after baseline. Patients were excluded if they stopped their DMT at least 6 months within baseline and if they received an unlicensed therapy such as mitoxantrone, cladribine, rituximab, ocrelizumab, siponimod, or autologous stem cell transplant. Case and control matching was done via MatchIT. Treatment with each included therapy reduced the conversion to secondary progressive MS compared to no treatment: glatiramer acetate or interferon-beta (Hazard Ratio 0.71; CI95 0.61 to 0.81), fingolimod (HR 0.37; CI95 0.22 to 0.62), natalizumab (HR 0.61; CI95 0.43 to 0.86), and alemtuzumab (HR 0.52; CI95 0.32 to 0.85). Patients who received glatiramer acetate or interferon-beta within 5 years of symptom presentation had reduced conversion rates compared to those who received treatment after 5 years (HR 0.77; CI95 0.61 to 0.98). When treatment escalated from glatiramer acetate or interferon-beta to fingolimod, natalizumab, or alemtuzumab, there was a reduction in conversion rates compared to those who remained on initial DMT (HR 0.76; CI95 0.66 to 0.88). Patients who started fingolimod, natalizumab, or alemtuzumab had reduced conversion rates compared to those started on glatiramer acetate or interferon-beta (HR 0.66; CI95 0.44-0.99).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

 

Tags: disease-modifying treatment (DMT)multiple sclerosis
Previous Post

1 in 5 US women report delayed contraceptive initiation after sexual debut

Next Post

Fecal microbiota transplantation improves remission rates in ulcerative colitis

RelatedReports

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

October 12, 2021
Quick Take: Safety and Efficacy of Ozanimod Versus Interferon Beta-1a in Relapsing Multiple Sclerosis (SUNBEAM)
Chronic Disease

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

August 17, 2021
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Improvements in therapeutic and managing standards associated with significant reduction in risk of persistent disability in patients with pediatric-onset multiple sclerosis

June 2, 2021
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Neurology

Ponesimod may be superior to teriflunomide for relapsing multiple scleorsis

April 5, 2021
Next Post
Elective colectomy associated with improved survival in ulcerative colitis

Fecal microbiota transplantation improves remission rates in ulcerative colitis

Quick Take: Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma: International Multicenter Cohort Study

Quick Take: Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma: International Multicenter Cohort Study

#VisualAbstract: Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer

#VisualAbstract: Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.